Canopy Growth’s Structural Wall Blocks Shareholder Gains from US Cannabis Reform
Published on 07/19/2026 at 17:32 | Redaktion boerse-global.de
The gap between Canopy Growth’s stock price and the regulatory optimism swirling around US medical marijuana is widening, and the culprit lies deep inside the company’s balance sheet. Shares closed at €0.8078 on Friday, down 2.91% on the day and now only 7.71% above the 52-week low of €0.75 touched on March 30. From the December high of €2.00, the stock has surrendered nearly 60% of its value. The 14-day relative strength index sits at 39.2, a reading that signals oversold territory has not yet been reached, while annualized 30-day volatility of 33.6% suggests more sharp swings lie ahead.
The disconnect stems from a Nasdaq-imposed accounting constraint: Canopy Growth does not consolidate the results of its US subsidiary, Canopy USA, into its own financial statements. That unit sells medical cannabis and would be the direct beneficiary of President Trump’s directive to federal agencies to reschedule the substance, as well as of the DEA’s recent hearings on reclassifying non-medical marijuana. But because the parent company’s earnings do not reflect that business, the regulatory tailwind fails to translate into a meaningful catalyst for the equity. Management has described the US market as a long-term opportunity and vowed to accelerate market access, but the immediate impact on reported results is nil.
That reality is underscored by the company’s fourth-quarter numbers, released June 15, which disappointed expectations. Net revenue came in at C$71.245 million (roughly US$51.94 million), and the loss per share landed at C$0.40 (US$0.29) — a deeper red-ink figure than the preliminary estimates had suggested. Analysts now forecast a loss per share of US$0.04 on revenue of about US$58.52 million for the current quarter. The next earnings report is due August 7, 2026.
Should investors sell immediately? Or is it worth buying Canopy Growth?
On the operational front, Canopy Growth has made strides in its home market. The acquisition of MTL Cannabis made it Canada’s largest medical cannabis provider by revenue, and the company has been restructuring costs and improving cultivation efficiency. Management has guided for positive adjusted EBITDA by fiscal 2027. But those gains are set against a punishing industry backdrop: wholesale cannabis prices in Canada have fallen roughly 17% since official tracking began, and an estimated three-quarters of consumers still buy from the black market, where a gram costs C$5.93 versus C$10.65 for legal product. The entire legal Canadian cannabis industry is valued at C$8.6 billion — a mere 0.3% of the country’s economic output — and past diversification efforts such as the investment in sports-drink brand BioSteel have weighed on results.
The six analysts covering the stock remain cautious, offering a consensus “Hold” rating split between one “Sell,” three “Hold” and two “Buy.” Institutional investors hold 3.33% of shares, and some funds increased their positions in the fiscal second quarter. Meanwhile, short interest stands at 22.62 million shares, representing 5.61% of the float, with a days-to-cover ratio of 2.8 — though that figure edged down 1.75% from the prior period. Management insider transactions also drew attention: CEO Luc Mongeau and board member Christelle Gedeon each sold shares on June 17 at US$0.9741, offloading 135,231 and 58,994 shares respectively, but the disposals were tax-related settlements of restricted stock units rather than open-market sales.
The stock’s trajectory from the 2018 post-legalization peak of US$52.03 to today’s sub-dollar valuation is a stark reminder of how far the company — and the broader Canadian sector — has fallen. For Canopy Growth, the real prize remains US market access through Canopy USA, but until that unit’s results are consolidated into the parent’s books, the share price will rely far more on operational execution in Canada than on headlines from Washington. August’s earnings will offer the next test of whether that execution can narrow the gap.
Ad
Canopy Growth Stock: New Analysis - 19 July
Fresh Canopy Growth information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
